Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

NCT06537674 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2+ Breast Cancer

Interventions

DRUG: Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection

Sponsor

Jiangsu Famous Medical Technology Co., Ltd.